# Safety and Tolerability of LIM-0705 in Healthy Male Subjects

> **NCT01060475** · PHASE1 · COMPLETED · sponsor: **Limerick BioPharma** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LIM-0705 and tacrolimus
- **DRUG:** LIM-0705 and tacrolimus
- **DRUG:** Placebo LIM-0705 and tacrolimus
- **DRUG:** Drug LIM-0705 and placebo tacrolimus

## Key facts

- **NCT ID:** NCT01060475
- **Lead sponsor:** Limerick BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2010-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01060475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01060475, "Safety and Tolerability of LIM-0705 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01060475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*